Abstract
Nine novel process impurities of N-[N-benzoyl-O-(2-dimethylaminoethyl)-l-tyrosyl]-l-phenylalaninol (Y101) observed during the laboratory optimization and later during its bulk synthesis are described in this article. The impurities were monitored by HPLC, and their structures were tentatively assigned on the basis of fragmentation patterns in LC−MS/MS and NMR spectroscopies. All of the impurities were synthesized, and their assigned constitutions were confirmed by co-injection in HPLC. In addition to the formation, synthesis, and characterization, the strategy for minimizing these impurities to a level accepted by the International Conference on Harmonisation (ICH) was also described.
Similar content being viewed by others
References
L.G. Yi, X.B. Xue, L.C. Xiao, H.Z. Ming, C.P. Xue, C.Z. Gui, L. Ying, Chinese Patent, CN 100480234C (2006)
L.Q. Chuan, W.C. Yin, H.S. Tao, Z. Wei, L. Wei, L. Jun, H.Z. Ming, Chin. Pharmacol. Bull. 28, 1389 (2012)
H.Z. Ming, Chin. J. Pharmacol. Toxicol. 25(Supple), 160 (2011)
B.X. Xu, Z.M. Huang, C.X. Liu, Z.G. Cai, W.D. Pan, P.X. Cao, X.J. Hao, G.Y. Liang, Bioorg. Med. Chem. 17, 3118 (2009)
J.Y. Qiu, B.X. Xu, Z.M. Huang, W.D. Pan, P.X. Cao, C.X. Liu, X.J. Hao, B.A. Song, G.Y. Liang, Bioorg. Med. Chem. 19, 5352 (2011)
ICH Q3A(R2) Impurities in new drug substances, international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH): Geneva, Switzerland (2006)
Z.X. Hu, Y.G. Zhang, Q. An, B.X. Xu, W.D. Pan, P.X. Cao, C.X. Liu, Z.M. Huang, W. Xia, J.Y. Qiu, G.Y. Liang, Tetrahedron 70, 9295 (2014)
C.V. Lu, J.J. Chen, W.R. Perrault, B.G. Conway, M.T. Maloney, Y. Wang, Org. Process. Res. Dev. 10, 272 (2006)
P. Wipf, C. Wang, Org. Lett. 8, 2381 (2006)
R.M. Rydzewski, L. Burrill, R. Mendonca, J.T. Palmer, M. Rice, R. Tahilramani, K.E. Bass, L. Leung, E. Gjerstad, J.W. Janc, L. Pan, J. Med. Chem. 49, 2953 (2006)
D.M. Shendage, R. Frölhlich, G. Haufe, Org. Lett. 6, 3675 (2004)
H.M. Franzén, G. Bessidskaia, V. Abedi, A. Nilsson, M. Nilsson, L. Olsson, Org. Process. Res. Dev. 6, 788 (2002)
S. Kamijo, S. Matsumura, M. Inoue, Org. Lett. 12, 4195 (2010)
Z. Sun, E. Botros, A. Su, Y. Kim, E. Wang, N.Z. Baturay, C. Kwon, J. Med. Chem. 43, 4160 (2000)
P. Lv, H. Li, J. Xue, L. Shi, H. Zhu, Eur. J. Med. Chem. 44, 908 (2009)
N. Ullah, K.M. Arafeh, Tetrahedron Lett. 50, 158 (2009)
G. Höfle, W. Steglich, H. Vorbrüggen, Angew. Chem. Int. Ed. Engl. 17, 569 (1978)
J.E. McMurry, J.H. Musser, M.S. Ahmad, L.C. Blaszczak, J. Org. Chem. 40, 1829 (1975)
J.S. Bindra, A. Grodski, J. Org. Chem. 42, 910 (1977)
Z.X. Hu, Q. An, K.F. Li, Y.G. Zhang, J.Y. Qiu, B.X. Xu, W.D. Pan, P.X. Cao, C.X. Liu, Z.M. Huang, W. Xia, G.Y. Liang, Org. Process. Res. Dev. 17, 1156 (2013)
D.R. Corbin, S. Schwarz, G.C. Sonnichsen, Catal. Today 37, 71 (1997)
R.D. Ashford, Ashford’s Dictionary of Industrial Chemicals, 3rd edn. (Wavelength Publications, England, 2011)
Acknowledgments
This work was supported by grants from the Ministry of Science and Technology of China (No. 2011ZX09102-009-2), the National Natural Science Fund of China (NSFC No. 30760292), and the Science and Technology Department of Guizhou Province (No. QKHZYZ [2012] 5054).
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Hu, Z., Liao, H., An, Q. et al. Process development of clinical anti-HBV drug Y101: identification and synthesis of novel impurities. Res Chem Intermed 42, 2577–2595 (2016). https://doi.org/10.1007/s11164-015-2169-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11164-015-2169-0